Skip to search formSkip to main contentSkip to account menu
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in anLower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rates of hospitalizationFor heart failure.
View on Wolters Kluwer
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
TLDR
Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased.
View on PubMed
A controlled trial of renal denervation for resistant hypertension.
TLDR
This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control.
View on PubMed
Rivaroxaban in patients with a recent acute coronary syndrome.
TLDR
In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in a double-blind, placebo-controlled trial.
View on PubMed
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
TLDR
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation are published, with a focus on patients with a history of prior heart failure.
View on PubMed
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
TLDR
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than amongThose who received placebo.
View on Wolters Kluwer
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
View on Elsevier
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.
TLDR
Among obese patients with uncontrolled type 2 diabetes, 3 years of intensive medical therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did medical therapy alone.
View on PubMed
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
View on PubMed
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
TLDR
Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License